News | April 08, 2022
Cadila Pharma launches world’s first three-dose rabies vaccine
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing
Neural sleeve first algorithm-powered bionic garment designed to help those with mobility issues due to multiple sclerosis, stroke, cerebral palsy, and other conditions, regain functional movement in everyday activities
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Circular revenues already at 16% of sales, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime and reusing refurbished parts and systems
Appoints Dr Rafiq Hasan as CEO
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
Key takeaways of Q3FY22 quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
